JPMorgan Chase & Co. Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $473.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target reduced by JPMorgan Chase & Co. from $475.00 to $473.00 in a research report sent to investors on Monday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on ALNY. The Goldman Sachs Group lifted their price objective on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research note on Tuesday, September 16th. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Raymond James Financial began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price objective for the company. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. Finally, BMO Capital Markets lifted their price target on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Twenty-four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $457.08.

Alnylam Pharmaceuticals Trading Up 0.2%

Alnylam Pharmaceuticals stock opened at $470.27 on Monday. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $485.28. The firm’s 50 day moving average price is $454.12 and its 200-day moving average price is $349.19. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The stock has a market cap of $61.64 billion, a P/E ratio of -190.39 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 8,924 shares of the stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the sale, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,103,454.05. Following the sale, the executive vice president directly owned 25,231 shares of the company’s stock, valued at $11,405,673.55. This represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 over the last three months. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALNY. Bessemer Group Inc. increased its holdings in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the period. Crossmark Global Holdings Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at about $275,000. Strs Ohio purchased a new stake in Alnylam Pharmaceuticals in the first quarter worth about $7,781,000. GAMMA Investing LLC increased its position in Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 77 shares during the period. Finally, Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.